Imugene : Final Cancer Vaccine Doses Delivered to GMP Depot in Singapore

• Final cancer vaccine doses successfully aseptically filled-and-finished in Switzerland and delivered to GMP-dedicated depot in Singapore
• Clinical-grade HER-Vaxx ready for despatch to trial sites in Hong Kong, Taiwan and Thailand

Since announcing in March the successful manufacture of the GMP batch of HER-Vaxx at piCHEM GmbH in Austria, the individual clinical doses have been aseptically filled-and-finished at a dedicated facility in Switzerland (Baccinex SA).

Imugene has engaged dedicated global life sciences clinical supply chain company Marken to manage the critical transport of its doses from Switzerland to Singapore, and then onto the individual trial sites throughout Asia. The centralised Singapore facility is a state-of-the-art GMP compliant depot.

Imugene COO Ms. Leslie Chong said, "This is yet another critical milestone met in our preparation for commencing our Phase 1B/2 clinical trial in patients with gastric cancer. It's very exciting to know our precious vaccine doses are safely stored, and ready for on-call despatch to our clinical sites in Hong Kong, Taiwan and Thailand."

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

In January 2016 Imugene announced a new partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.

For further information, please visit www.imugene.com.

Sign up to follow @TeamImugene on Twitter at http://www.twitter.com/TeamImugene. To follow Imugene on Facebook visit www.facebook.com/imugene.

Leslie Chong, Chief Operating Officer

Tel: +61 458 040 433 (Australia), leslie.chong[at]imugene.com

IMUGENE LIMITED ACN 009 179 551 Phone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com